{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T02:14:32Z","timestamp":1788056072070,"version":"build-2784847793"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Preventive Medicine"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ypmed.2021.106820","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T15:29:51Z","timestamp":1632929391000},"page":"106820","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Naloxone dispensing among the commercially insured population in the United States from 2015 to 2018"],"prefix":"10.1016","volume":"153","author":[{"given":"Christopher","family":"Dunphy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Gery P.","family":"Guy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ypmed.2021.106820_bb0005","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/jamainternmed.2019.0272","article-title":"Association between state laws facilitating pharmacy distribution of naloxone and risk of fatal overdose","volume":"179","author":"Abouk","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.ypmed.2021.106820_bb0010","author":"Association of State and Territorial Health Officials"},{"key":"10.1016\/j.ypmed.2021.106820_bb0015","first-page":"122","article-title":"Academic detailing pilot for naloxone prescribing among primary care providers in San Francisco","volume":"49","author":"Behar","year":"2017","journal-title":"Fam. Med."},{"issue":"4","key":"10.1016\/j.ypmed.2021.106820_bb0020","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.japh.2019.11.010","article-title":"Comparison of naloxone prescribing patterns due to educational outreach conducted by full-time and part-time academic detailers at the U.S. Veterans Health Administration","volume":"60","author":"Bounthavong","year":"2020","journal-title":"J. AM. Pharm. Assoc."},{"issue":"2","key":"10.1016\/j.ypmed.2021.106820_bb0025","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMra1202561","article-title":"Management of opioid analgesic overdose","volume":"367","author":"Boyer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ypmed.2021.106820_bb0030","author":"CBSNews"},{"key":"10.1016\/j.ypmed.2021.106820_bb0035","author":"Centers for Medicare and Medicaid Services"},{"issue":"3","key":"10.1016\/j.ypmed.2021.106820_bb0040","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/ADM.0000000000000034","article-title":"A systematic review of community opioid overdose prevention and naloxone distribution programs","volume":"8","author":"Clark","year":"2014","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.ypmed.2021.106820_bb0045","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.drugpo.2019.06.001","article-title":"Pharmacist dispensed naloxone: knowledge, availability, participation, and cost in selected California counties","volume":"71","author":"Darracq","year":"2019","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.ypmed.2021.106820_bb0050","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.10.013","article-title":"Legal changes to increase access to naloxone for opioid overdose reversal in the United States","volume":"157","author":"Davis","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.ypmed.2021.106820_bb0055","doi-asserted-by":"crossref","first-page":"105932","DOI":"10.1016\/j.ypmed.2019.105932","article-title":"Over the counter naloxone needed to save lives in the United States","volume":"130","author":"Davis","year":"2020","journal-title":"Prev. Med."},{"issue":"15","key":"10.1016\/j.ypmed.2021.106820_bb0060","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.2016.1464","article-title":"CDC guideline for prescribing opioids for chronic pain United States, 2016","volume":"315","author":"Dowell","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ypmed.2021.106820_bb0065","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.japh.2019.09.007","article-title":"Impact of student pharmacist-led naloxone academic detailing at community pharmacies in Texas","volume":"60","author":"Evoy","year":"2020","journal-title":"J. Am. Pharm. Assoc."},{"issue":"5","key":"10.1016\/j.ypmed.2021.106820_bb0070","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.3209","article-title":"Naloxone prescriptions among commercially insured individuals at high risk of opioid overdose","volume":"2","author":"Follman","year":"2019","journal-title":"JAMA Netw. Open"},{"issue":"8","key":"10.1016\/j.ypmed.2021.106820_bb0075","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1177\/1357633X18782090","article-title":"Evaluation of an innovative tele-education intervention in chronic pain management for primary care clinicians practicing in underserved areas","volume":"25","author":"Furlan","year":"2018","journal-title":"J. Telemed. Telecare"},{"key":"10.1016\/j.ypmed.2021.106820_bb0080","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.drugalcdep.2018.05.014","article-title":"Do naloxone access laws increase outpatient naloxone prescriptions?","volume":"190","author":"Gertner","year":"2018","journal-title":"Evid. Med. Drug Alcohol Depend."},{"issue":"4","key":"10.1016\/j.ypmed.2021.106820_bb0085","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/ADM.0000000000000492","article-title":"Naloxone availability and pharmacy staff knowledge of standing order for naloxone in Pennsylvania pharmacies","volume":"13","author":"Graves","year":"2019","journal-title":"J. Addict. Med."},{"issue":"23","key":"10.1016\/j.ypmed.2021.106820_bb0090","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1056\/NEJMp1609578","article-title":"The rising price of naloxone \u2013 risks to efforts to stem overdose deaths","volume":"375","author":"Gupta","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"31","key":"10.1016\/j.ypmed.2021.106820_bb0095","doi-asserted-by":"crossref","first-page":"679","DOI":"10.15585\/mmwr.mm6831e1","article-title":"Vital signs: pharmacy-based naloxone dispensing \u2013 United States, 2012\u20132018","volume":"68","author":"Guy","year":"2019","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.ypmed.2021.106820_bb0100","first-page":"1","article-title":"Concurrent naloxone dispensing among individuals with high-risk opioid prescriptions, USA, 2015\u20132019","author":"Guy","year":"2021","journal-title":"J. Gen. Intern. Med."},{"issue":"11","key":"10.1016\/j.ypmed.2021.106820_bb0110","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/MLR.0000000000000805","article-title":"Trends in opioid related inpatient stays shifted after the US transitioned to ICD-10-CM diagnosis coding in 2015","volume":"55","author":"Heslin","year":"2017","journal-title":"Med. Care"},{"key":"10.1016\/j.ypmed.2021.106820_bb0115","author":"IBM Watson Health"},{"issue":"5","key":"10.1016\/j.ypmed.2021.106820_bb0120","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jama.2019.7988","article-title":"Naloxone co-prescribing to patients receiving prescription opioids in the Medicare Part D Program, United States, 2016\u20132017","volume":"322","author":"Jones","year":"2019","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.ypmed.2021.106820_bb0125","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1111\/add.14635","article-title":"Do electronic health record prompts increase take-home naloxone administration for emergency department patients after an opioid overdose?","volume":"114","author":"Marino","year":"2019","journal-title":"Addiction"},{"key":"10.1016\/j.ypmed.2021.106820_bb0130","series-title":"CDC Compilation of Benzodiazepines, Muscle Relaxants, Stimulants, Zolpidem, and Opioid Analgesics With Oral Morphine Milligram Equivalent Conversion Factors, 2018 Version","author":"National Center for Injury Prevention and Control","year":"2018"},{"key":"10.1016\/j.ypmed.2021.106820_bb0135","author":"Prescription Drug Abuse Policy System"},{"issue":"6","key":"10.1016\/j.ypmed.2021.106820_bb0145","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.6215","article-title":"Association of naloxone coprescription laws with naloxone prescription dispensing in the United States","volume":"2","author":"Sohn","year":"2019","journal-title":"JAMA Netw. Open"},{"issue":"5","key":"10.1016\/j.ypmed.2021.106820_bb0150","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.japh.2020.01.030","article-title":"Evaluation in naloxone access, pricing, and barriers to dispensing in Tennessee retail community pharmacies","volume":"60","author":"Spivey","year":"2020","journal-title":"J. Am. Pharm. Assoc."},{"key":"10.1016\/j.ypmed.2021.106820_bb0155","author":"Time"},{"key":"10.1016\/j.ypmed.2021.106820_bb0160","author":"U.S. Department of Health and Human Services"},{"key":"10.1016\/j.ypmed.2021.106820_bb0165","author":"U.S. Department of Health and Human Services"},{"issue":"3","key":"10.1016\/j.ypmed.2021.106820_bb0170","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1080\/08897077.2016.1142921","article-title":"Internal medicine resident knowledge, attitudes, and barriers to naloxone prescription in hospital and clinic settings","volume":"37","author":"Wilson","year":"2016","journal-title":"Subst. Abus."},{"issue":"11","key":"10.1016\/j.ypmed.2021.106820_bb0175","doi-asserted-by":"crossref","first-page":"290","DOI":"10.15585\/mmwr.mm6911a4","article-title":"Drug and opioid-involved overdose deaths - United States, 2017\u20132018","volume":"69","author":"Wilson","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.ypmed.2021.106820_bb0180","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.drugalcdep.2018.04.020","article-title":"State naloxone access laws are associated with an increase in the number of naloxone prescriptions dispensed in retail pharmacies","volume":"189","author":"Xu","year":"2018","journal-title":"Drug Alcohol Depend."}],"container-title":["Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091743521003893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091743521003893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T10:18:50Z","timestamp":1758795530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091743521003893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":34,"alternative-id":["S0091743521003893"],"URL":"https:\/\/doi.org\/10.1016\/j.ypmed.2021.106820","relation":{},"ISSN":["0091-7435"],"issn-type":[{"value":"0091-7435","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Naloxone dispensing among the commercially insured population in the United States from 2015 to 2018","name":"articletitle","label":"Article Title"},{"value":"Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ypmed.2021.106820","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106820"}}